A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naive Subjects With Moderately-to-Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Ustekinumab (Primary) ; Adalimumab
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SEAVUE
- Sponsors Janssen
- 24 Jan 2019 Planned End Date changed from 22 Oct 2020 to 23 Dec 2020.
- 31 Oct 2018 Planned End Date changed from 1 Dec 2020 to 22 Oct 2020.
- 31 Aug 2018 Biomarkers information updated